61 results
Page 2 of 4
8-K
EX-99.1
n11ofmp
10 Aug 20
Recro Reports Second Quarter 2020 Financial Results
7:06am
8-K
EX-2.1
8iyy1 lrfkzgr9bv0
26 Nov 19
Entry into a Material Definitive Agreement
4:54pm
8-K
EX-99.1
ftjb756l 7y
5 Nov 19
Recro Pharma’s Board of Directors Approves Separation of Acute
7:07am
8-K
EX-99.1
spxbxpal4p5z1 qkl
5 Apr 19
Cost Associated with Exit or Disposal Activities
4:01pm
8-K
EX-99.1
j5uwzabsstes9v
28 Mar 19
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
6:05am
8-K
EX-99.1
s2cr5g2kdpg47dp171
22 Mar 19
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
4:17pm
424B5
6vojfq 0pp0
19 Feb 19
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
49ecfvhz8b7cqxq 8miu
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
7zy 7a90td
10 Dec 18
Other Events
2:07pm
8-K
EX-99.1
sphvrcu5izrfni3j4dgq
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.1
m08788
9 Oct 18
Recro Pharma Announces PDUFA Date for IV Meloxicam
6:07am